Development of a gene therapy approach to enhance the metabolism of bioreductive drugs.
Read Online
Share

Development of a gene therapy approach to enhance the metabolism of bioreductive drugs. by Margaret Murray

  • 985 Want to read
  • ·
  • 14 Currently reading

Published by The Author] in [s.l .
Written in English


Book details:

Edition Notes

Thesis (D.Phil.) - University of Ulster, 1999.

ID Numbers
Open LibraryOL18518522M

Download Development of a gene therapy approach to enhance the metabolism of bioreductive drugs.

PDF EPUB FB2 MOBI RTF

Keywords: Gene Therapy, Gene Delivery, Metabolic Disorders, Inborn Errors of Metabolism, Genomic Medicine, Therapy for Rare Disease INTRODUCTION In the early s, the concept of gene therapy became a reality when an exogenous gene was delivered Cited by: 7.   This approach may help to overcome cytotoxicity in physiologically normal tissue where the oxygen tension can be sufficiently low to activate HIF-1 but, depending on the class of bioreductive drug utilised, too high for drug-activation. In cancer gene therapy, treatment efficacy may be enhanced if the cytotoxin produced has a good bystander by:   Bioreductive drugs undergo metabolic reduction to generate cytotoxic metabolites. This process is facilitated by bioreductive enzymes and the lower oxygen conditions present in solid tumours compared to normal tissues. Because of this specificity, bioreductive drugs have enormous potential to contribute to modern cancer therapy. Examples undergoing clinical trials includeN-oxides such as Cited by:   The biotechnology sector has seen important progress in the development of groundbreaking therapies in recent years, especially in the areas of immunotherapy and cell and gene therapy. In gene therapy alone, there are now clinical research programs targeting almost 50 different indications, up from only 10 a few years ago, 1 and the rate of.

Gene therapy (also called human gene transfer) is a medical field which focuses on the utilization of the therapeutic delivery of nucleic acid into a patient's cells as a drug to treat disease. The first attempt at modifying human DNA was performed in by Martin Cline, but the first successful nuclear gene transfer in humans, approved by the National Institutes of Health, was performed in.   Clinical development of gene therapy began over 20 years ago. Currently there are more than ongoing gene therapy clinical trials that are regulated by the Office of Cellular, Tissue, and Gene Therapies (OCTGT) in the Center for Biologics Evaluation and Research of the US Food and Drug Administration (FDA).Cited by: 6. metabolism necessitate on-going studies of its biotransformation. In the first chapter, the principles underlying drug absorption, distribution, metabolism and elimination are described, with drug metabolism highlighted within the context of these fundamental processes. Chapters 2 and 3 deal with the chemistry of drug biotransformation. Cancer chemotherapy and drug metabolism. to bioreductive drugs such as tirapazamine, a gene therapy must be nous PR in a gene therapy approach, unlike high endogenous. levels, would.

The great potential for gene therapy to treat a wide range of diseases has led to high expectations with the first marketing approval of an adeno-associated virus (AAV) serotype 1-based gene therapy in (Glybera for the treatment of lipoprotein lipase deficiency) by the European Medical Agency and the successful completion of a phase 3 clinical trial of an AAV2-based investigational Cited by: 1. I see that noted geneticist George Church has been discussing his new company Rejuvenate Bio in the media. The projects undertaken there are the logical progression of attempts to slow aging with pharmaceuticals, moving them into the era of gene is still guided by the a philosophy of what Aubrey de Grey would call "messing with metabolism.". Gene-directed enzyme prodrug therapy (GDEPT) is an attractive approach to cancer treatment, in which the non-toxic prodrugs are converted to highly cytotoxic derivatives by enzymes expressed Author: William Denny.   Making gene therapy safer. More than 20 years ago, children born with a genetic disorder called severe combined immunodeficiency were the first people to be treated with gene therapy. It .